PTI stock is moving higher in Tuesday’s session following the news that Proteostasis Therapeutics Inc (NASDAQ:PTI) received orphan drug designation in the EU for PTI-428, its treatment for cystic fibrosis.
Orphan Drug DesignationBoston, Massachusetts-based Proteostasis Therapeutics stock enjoyed a rally in early trade on Tuesday after news came through that its lead candidate PTI-428 has been granted the status of an orphan drug candidate by the European Commission. The product in question is meant for the treatment of cystic fibrosis, and needless to say, it is a major breakthrough for the company.
The ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.